Home › Calculator › ALLO Dividend Calculator 2026
ALLO Dividend DRIP Calculator 2026
96.15% YieldHealthcareAllogene Therapeutics, Inc. · NASDAQ
Price: $2.08 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ALLO pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ALLO snowball 📈
$10,000 in ALLO → $8.43M in 10 years · $344,474.33/month
About Allogene Therapeutics, Inc. (ALLO) — Dividend Analysis 2026
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Compare ALLO with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ALLO DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ALLO position with:
🌍 ALLO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ALLO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 96.15% | 93.35% | $9,615 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 81.73% | 78.93% | $8,173 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 76.92% | 74.12% | $7,692 / yr |
| 🇬🇧 UK ISA | 0% | 96.15% | 93.35% | $9,615 / yr |
| 🇬🇧 UK Taxable | 8.75% | 87.74% | 84.94% | $8,774 / yr |
| 🇨🇦 TFSA | 0% | 96.15% | 93.35% | $9,615 / yr |
| 🇨🇦 CA Taxable | 25% | 72.11% | 69.31% | $7,211 / yr |
| 🇦🇺 Super (pension) | 15% | 81.73% | 78.93% | $8,173 / yr |
| 🇦🇺 AU Taxable | 30% | 67.30% | 64.50% | $6,730 / yr |
| 🇩🇪 DE Taxable | 26.375% | 70.79% | 67.99% | $7,079 / yr |
| 🇫🇷 FR Taxable | 30% | 67.30% | 64.50% | $6,730 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ALLO Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ALLO Dividend Payment Schedule
ALLO pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ALLO vs Healthcare Benchmarks
How ALLO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ALLO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ALLO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-07-01 | 476,190 | $2.11 | $1.00M | ||
| A-Award | 2026-07-01 | 134,530 | — | — | ||
| M-Exempt | 2026-06-18 | 47,700 | — | — | ||
| A-Award | 2026-06-18 | 95,400 | — | — | ||
| M-Exempt | 2026-06-18 | 47,700 | — | — | ||
| A-Award | 2026-06-18 | 95,400 | — | — | ||
| A-Award | 2026-06-18 | 144,400 | $2.00 | $288.8K | ||
| A-Award | 2026-06-18 | 95,400 | — | — | ||
| A-Award | 2026-06-18 | 95,400 | — | — | ||
| A-Award | 2026-06-18 | 95,400 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ALLO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Allogene Therapeutics, Inc. (ALLO) is currently trading at $2.08, 94% below its 52-week high. The current dividend yield is 96.15% based on an annual payout of $2.00 per share.
ALLO (Allogene Therapeutics, Inc.) — 96.15% Dividend Yield Analysis
Allogene Therapeutics, Inc. (ALLO) is a healthcare stock currently trading at $2.08 with a dividend yield of 96.15%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (96.15%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.